SCIENCE  |  SUPPLEMENTS

Magnesium L-Threonate

Magnesium L-threonate (Magtein®) is a highly bioavailable form of magnesium that has been shown to effectively increase magnesium levels in the brain and neurons. Unlike other magnesium supplements, it crosses the blood-brain barrier more efficiently, making it particularly beneficial for cognitive health.

Magnesium_threonate

Recent studies have highlighted the potential of specific compounds to improve brain function and combat cognitive decline. One study, published in Nutrients (2022), examined the effects of Magtein®PS, a magnesium L-threonate and phosphatidylserine-based supplement with vitamins C and D, on cognitive functions in 109 healthy Chinese adults. The double-blind, placebo-controlled study found that participants who received Magtein®PS showed significant improvements in memory and cognition, particularly among older participants.

Another study, published in the Journal of Alzheimer’s Disease (2016), investigated MMFS-01, a synapse density enhancer, in treating cognitive impairment in adults aged 50-70. This randomized, double-blind, placebo-controlled trial involved 44 participants and demonstrated that MMFS-01 significantly improved overall cognitive ability and nearly restored impaired executive function. However, strong placebo effects on sleep and anxiety made it difficult to determine the specific benefits of MMFS-01 on these aspects.

These findings suggest that both Magtein®PS and MMFS-01 hold promise for enhancing cognitive function and addressing cognitive impairment, offering potential benefits for different age groups and cognitive challenges.

PUBLICATIONS

  1. A Magtein(®), Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults.
          • Nutrients. 2022 Dec 8;14(24):5235.
          • Design: Double-blind, placebo-controlled study on 109 healthy Chinese adults aged 18-65 years evaluating Magtein®PS on cognitive benefits.
          • Summary: Subjects receiving Magtein®PS showed significant improvements in all five subcategories of “The Clinical Memory Test” and overall memory quotient scores compared to the control group. Older participants showed more improvement than younger participants.
  2. Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.
          • J Alzheimers Dis. 2016;49(4):971-90.
          • Design: Randomized, double-blind, placebo-controlled, parallel-designed trial on older adult subjects aged 50-70 with cognitive impairment.
          • Summary: MMFS-01 treatment significantly improved overall cognitive ability relative to placebo and nearly restored impaired executive function. Strong placebo effects on sleep and anxiety obscured potential benefits in these areas.
STAY INFORMED

    Be up to date with
    our protocols

    APPLY TO

    WORK WITH US
    MEET THE
    BRIDGE TEAM